These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21157382)

  • 1. Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.
    Stuart JE; Lusis EA; Scheck AC; Coons SW; Lal A; Perry A; Gutmann DH
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):1-12. PubMed ID: 21157382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
    Schulten HJ; Hussein D
    PLoS One; 2019; 14(5):e0215452. PubMed ID: 31083655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.
    Schulten HJ; Hussein D; Al-Adwani F; Karim S; Al-Maghrabi J; Al-Sharif M; Jamal A; Al-Ghamdi F; Baeesa SS; Bangash M; Chaudhary A; Al-Qahtani M
    PLoS One; 2016; 11(4):e0153681. PubMed ID: 27096627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
    Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
    Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
    Fèvre-Montange M; Champier J; Durand A; Wierinckx A; Honnorat J; Guyotat J; Jouvet A
    Int J Oncol; 2009 Dec; 35(6):1395-407. PubMed ID: 19885562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
    Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
    Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.
    Watson MA; Gutmann DH; Peterson K; Chicoine MR; Kleinschmidt-DeMasters BK; Brown HG; Perry A
    Am J Pathol; 2002 Aug; 161(2):665-72. PubMed ID: 12163391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome.
    Korshunov A; Shishkina L; Golanov A
    Int J Cancer; 2003 May; 104(6):728-34. PubMed ID: 12640680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
    Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
    J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
    Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ
    Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
    Bie L; Zhao G; Ju Y; Zhang B
    Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of ErbB receptors and ligands in human meningiomas.
    Laurendeau I; Ferrer M; Garrido D; D'Haene N; Ciavarelli P; Basso A; Vidaud M; Bieche I; Salmon I; Szijan I
    Cancer Invest; 2009 Jul; 27(6):691-8. PubMed ID: 19440932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of proliferation index and expression of the RNA component of human telomerase (hTR) in papillary meningiomas.
    Rushing EJ; Colvin SM; Gazdar A; Miura N; White CL; Coimbra C; Burns DK
    J Neurooncol; 1999; 45(3):199-207. PubMed ID: 10845390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas.
    Nagashima G; Aoyagi M; Yamamoto S; Wakimoto H; Tamaki M; Yamamoto K; Fujimoto T; Hirakawa K
    Clin Neurol Neurosurg; 2001 Apr; 103(1):13-8. PubMed ID: 11311470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.